XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.1

Revenue (Tables)

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following table summarizes our revenue recognized in our consolidated condensed statements of operations:

			Three Months Ended March 31,
			2023						2022
Net product revenue			$	6,238.2					$	7,132.9
Collaboration and other revenue(1)			721.8						677.1
Revenue			$	6,960.0					$	7,810.0

(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $25.1 million and $53.2 million during the three months ended March 31, 2023 and 2022, respectively.

The following table summarizes revenue by product for the three months ended March 31, 2023 and 2022:

			Three Months Ended March 31,
			2023												2022
			U.S.			Outside U.S.			Total						U.S.			Outside U.S.			Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®			$	1,547.4		$	429.7		$	1,977.1					$	1,313.9		$	427.4		$	1,741.3
Jardiance(1)			329.4			248.1			577.5						229.8			189.7			419.4
Mounjaro®			536.4			32.0			568.5						—			—			—
Humalog® (2)			271.6			189.3			460.9						368.9			249.3			618.2
Humulin®			198.8			53.2			252.0						190.4			82.8			273.2
Basaglar®			135.4			73.9			209.3						119.3			72.2			191.5
Other diabetes			56.0			89.2			145.1						54.3			90.2			144.6
Total diabetes			3,075.0			1,115.4			4,190.4						2,276.6			1,111.6			3,388.2
Oncology:
Verzenio®			461.1			289.8			750.9						301.5			167.9			469.4
Cyramza®			100.6			136.1			236.8						79.2			151.1			230.3
Erbitux®			118.8			11.1			129.9						109.7			13.0			122.7
Alimta®			20.1			38.1			58.2						254.3			89.7			343.9
Other oncology			52.8			127.5			180.2						39.0			147.5			186.7
Total oncology			753.4			602.6			1,356.0						783.7			569.2			1,353.0
Immunology:
Taltz®			312.2			214.8			527.0						307.2			180.8			488.1
Olumiant® (3)			42.3			186.5			228.9						71.3			184.3			255.6
Other immunology			—			22.0			22.0						—			4.5			4.5
Total immunology			354.5			423.3			777.8						378.5			369.6			748.1
Neuroscience:
Emgality®			108.7			45.6			154.3						108.3			41.0			149.3
Other neuroscience			35.8			170.4			206.2						45.1			203.4			248.4
Total neuroscience			144.5			216.0			360.5						153.4			244.4			397.7
Other:
Forteo®			70.7			51.7			122.3						70.2			67.3			137.4
Cialis®			7.6			92.7			100.3						6.9			210.8			217.7
COVID-19 antibodies(4)			—			—			—						1,455.2			14.7			1,469.8
Other			30.5			22.2			52.8						50.1			47.8			98.1
Total other			108.7			166.6			275.3						1,582.4			340.6			1,923.0
Revenue			$	4,436.2		$	2,523.9		$	6,960.0					$	5,174.6		$	2,635.4		$	7,810.0

Numbers may not add due to rounding.

(1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.

(2) Humalog revenue includes insulin lispro.

(3) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.

(4) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.

The following table summarizes revenue by geographical area:

			Three Months Ended March 31,
			2023						2022
Revenue—to unaffiliated customers(1):
U.S.			$	4,436.2					$	5,174.6
Europe			1,090.9						1,067.3
Japan			387.2						410.2
China			372.7						406.5
Other foreign countries			673.1						751.5
Revenue			$	6,960.0					$	7,810.0

Numbers may not add due to rounding.

(1) Revenue is attributed to the countries based on the location of the customer.

Schedule of amounts recorded for contract liabilities

The following table summarizes contract liability balances:

			March 31, 2023						December 31, 2022
Contract liabilities			$	220.3					$	219.2

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration